These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17716427)

  • 21. ABPI call for NICE guidance to be made mandatory.
    Tiner R
    Lancet Oncol; 2003 Apr; 4(4):203-4. PubMed ID: 12681260
    [No Abstract]   [Full Text] [Related]  

  • 22. NICE system...shame about the side-effects.
    McVie G
    Lancet Oncol; 2003 Apr; 4(4):203. PubMed ID: 12681259
    [No Abstract]   [Full Text] [Related]  

  • 23. Data briefing. NICE (National Institute for Clinical Excellence).
    Appleby J
    Health Serv J; 2000 Jun; 110(5708):32. PubMed ID: 11183800
    [No Abstract]   [Full Text] [Related]  

  • 24. The NICE cost-effectiveness threshold: what it is and what that means.
    McCabe C; Claxton K; Culyer AJ
    Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A furore too far: the widespread disquiet undermining NICE.
    Carlisle D
    Health Serv J; 2006 Jun; 116(6011):14-5. PubMed ID: 16827515
    [No Abstract]   [Full Text] [Related]  

  • 26. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 27. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of probabilistic decision models in technology assessment : the case of total hip replacement.
    Briggs A; Sculpher M; Dawson J; Fitzpatrick R; Murray D; Malchau H
    Appl Health Econ Health Policy; 2004; 3(2):79-89. PubMed ID: 15702945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 32. NICE work--providing guidance to the British National Health Service.
    Rawlins MD
    N Engl J Med; 2004 Sep; 351(14):1383-5. PubMed ID: 15459297
    [No Abstract]   [Full Text] [Related]  

  • 33. Unintended consequences of applying economic evaluation.
    Oliver A
    J Health Serv Res Policy; 2002 Jul; 7(3):129-30. PubMed ID: 12171741
    [No Abstract]   [Full Text] [Related]  

  • 34. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valuing health States for use in cost-effectiveness analysis.
    Brazier J
    Pharmacoeconomics; 2008; 26(9):769-79. PubMed ID: 18767897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health technology appraisal of interventional procedures: comparison of rapid and slow methods.
    Warren V
    J Health Serv Res Policy; 2007 Jul; 12(3):142-6. PubMed ID: 17716416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nice or not so nice.
    McColgan K
    J Perioper Pract; 2010 Nov; 20(11):386. PubMed ID: 21162353
    [No Abstract]   [Full Text] [Related]  

  • 40. Let cost effectiveness models be open to scrutiny.
    Poole C; Agrawal S; Currie CJ
    BMJ; 2007 Oct; 335(7623):735. PubMed ID: 17932167
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.